|By PR Newswire||
|April 9, 2014 06:00 AM EDT||
SANTA ROSA, Calif., April 9, 2014 /PRNewswire/ -- A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma. Conducted by researchers at the Cancer Research Laboratory at Indiana University Health, Indiana University School of Medicine, the preclinical study showed that honokiol (HonoPure®, EcoNugenics, Santa Rosa, CA) inhibited two highly aggressive renal cell carcinoma (RCC) cell lines. The extract also restricted the invasive potential of renal carcinoma cells, and modulated expression of genes involved in the suppression of metastasis. These results were presented at the 2014 American Association for Cancer Research Annual Meeting in San Diego, CA.
"This is an excellent first step toward developing a new treatment for aggressive renal cancer," says lead investigator Dr. Daniel Sliva, adjunct associate professor at the Indiana University School of Medicine. "This cancer is well known for its ability to metastasize. However, honokiol may be able to limit proliferation, suppress invasiveness and help prevent the cancer from spreading."
Because of its indistinct symptoms, RCC is often diagnosed in later stages, making it particularly deadly. As many as 70 percent of RCC patients experience recurrent disease, despite surgery. Around 25 percent develop metastases. Furthermore, few effective therapies are available.
Results of this study were particularly strong for one of the cell lines, showing that honokiol inhibited migration in a dose-dependent manner. DNA analysis also showed honokiol increased expression of specific genes which suppress metastasis. Because metastasis is often what kills patients, finding a way to control it could save lives.
Derived from Magnolia officinalis bark which is used throughout traditional Asian medicine, honokiol has demonstrated the ability to inhibit a number of cancers through multiple mechanisms of action. Specifically, the extract has been shown to modulate genes associated with cancer growth and aggressiveness. Previous preclinical research found honokiol inhibits multiple cancer cell types: breast, prostate, colon, liver, lung, pancreatic, skin, blood; induces apoptosis of cancer cells through multiple pathways; inhibits angiogenesis and proliferation through the lymph system, and acts as a powerful anti-inflammatory, antioxidant agent, among other findings.
"This study substantiates the need for further research which could lead to more effective cancer treatments," says Dr. Sliva. "Our next step is to better understand the molecular mechanisms underlying honokiol's anticancer activity, confirm our results with preclinical studies in mice, and progress to human clinical trials."
Better Health Publishing
SOURCE Better Health Publishing
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
Mar. 26, 2017 05:00 PM EDT Reads: 3,558
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, will posit that disruption is inevitable for c...
Mar. 26, 2017 05:00 PM EDT Reads: 2,092
Mar. 26, 2017 03:30 PM EDT Reads: 6,505
Mar. 26, 2017 03:15 PM EDT Reads: 2,783
Mar. 26, 2017 03:00 PM EDT Reads: 10,524
Mar. 26, 2017 02:45 PM EDT Reads: 926
Mar. 26, 2017 02:30 PM EDT Reads: 1,720
Mar. 26, 2017 02:15 PM EDT Reads: 4,330
Mar. 26, 2017 02:00 PM EDT Reads: 3,370
Mar. 26, 2017 01:45 PM EDT Reads: 8,483
Mar. 26, 2017 01:45 PM EDT Reads: 1,814
Mar. 26, 2017 01:15 PM EDT Reads: 2,106
Mar. 26, 2017 01:15 PM EDT Reads: 3,550
Mar. 26, 2017 12:45 PM EDT Reads: 1,278
Mar. 26, 2017 12:45 PM EDT Reads: 1,892